Athersys, Inc.: Represented ING Barings (Furman Selz) in a private placement of $10 million of Class C convertible preferred stock of Athersys, a clinical stage biopharmaceutical and genomics company.

Clovis Oncology: Represented this developer and marketer of anti-cancer drugs since its inception and in various acquisition-related transactions, principal licensing agreements and the following financings:

• $90 million public offering of common stock.
• $250 million 144A offering of convertible senior notes.
• $300 million underwritten public offering of convertible senior notes.
• $100 million underwritten public offering of common stock.
• $235.75 million underwritten public offering of common stock.
• $345 million underwritten public offerings of common stock.
• $275 million underwritten public offering of common stock.
• $287.5 million 144A offering of convertible senior notes.
• $275 million underwritten public offering of common stock.

Epigenomics AG: Represented Morgan Stanley Bank AG on the rights issue of German molecular diagnostics company Epigenomics, a developer and commercializer of proprietary products for the screening and diagnosis of cancer.

IPF Partners: Represented IPF Partners in a venture bond financing for French clinical stage biopharmaceutical company Adocia.

Synageva BioPharma Corp.: Represented the underwriters, led by joint book-running managers Goldman, Sachs & Co. and J.P. Morgan Securities LLC, in Synageva’s $308 million public offering of common stock.

SeraCare Life Sciences, Inc.: Conducted an internal investigation on behalf of the Audit Committee of SeraCare.

Ekkio/Q-Biologicals: Represented Ekkio and its portfolio company, Amatsigroup, in the acquisition of Q-Biologicals, a leading provider of process development and biomanufacturing services.

Tikehau/Cisbio Bioassays/Abenex: Represented Tikehau on the financing aspects of the acquisition of Cisbio Bioassays by Abenex.

Valtech Cardio/HeartWare: Represented Valtech Cardio in its proposed acquisition by HeartWare, a combination that will help deliver transformative products to patients with advanced heart failure and degenerative heart conditions.